USFDA successfully concludes inspection at Piramal Pharma Ahmedabad facility
Mumbai: Piramal Pharma has announced that the US Food and Drug Administration (US FDA) has successfully concluded a Pre-Approval Inspection ('PAI') with Zero Form - 483 observations and No Action Indicated (NAI) designation at the Company's PPDS Ahmedabad facility.
The inspection was conducted from 10th July 2024 to 12th July, 2024.
Read also: USFDA successfully concludes inspection at Piramal Pharma USA facility
"Successful completion of this wholistic inspection at PPDS Ahmedabad facility, will now enable access to our high-end analytical capabilities to our customers for their clinical and commercial batches from an FDA approved site. The Company remains committed to maintain the highest standards of compliance," the Company stated in a BSE filing.
Read also: Piramal Pharma Lexington facility successfully completes USFDA Inspection
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.
PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies.
In addition, PPL has a joint venture with Allergan. In October 2020, the company received a growth equity investment from the Carlyle Group.
Read also: Piramal Alternatives infuses Rs 110 crore in Biodeal Pharma
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd